Further, multiple studies demonstrated that the NF-κB signaling pathway is a promising therapeutic target of ALI/ARDS and other inflammatory diseases, including arthritis, pulmonary fibrosis, asthma and hepatitis [17,18,21]. Here, NFKB1 is linked to arthritic joint disease.